Long term pulmonary impairment following a single exposure to methyl isocyanate.
Groups of guinea pigs were exposed for 3 hr to 6, 13, 19, 27, or 37 ppm of methyl isocyanate (MIC). Pulmonary performance was evaluated immediately postexposure and for a period of 1 year in the animals surviving 19 or 37 ppm of MIC. At 6 and 13 ppm deterioration of pulmonary performance was observed but complete recovery occurred within a few weeks. In those animals surviving 19 or 37 ppm some recovery occurred but a long lasting impairment of pulmonary performance was observed. One year after a single exposure to MIC these animals presented a condition best described as chronic obstructive lung disease. Using flow-volume measurements during air breathing and during CO2 challenge, animals surviving at 19 or 37 ppm presented typical abnormalities associated with airflow limitation along the conducting airways. One year after exposure lung hyperinflation was also present. At this time the poor ventilatory response to CO2 was due to mechanical limitation of lung expansion during inspiration and airflow limitation during expiration. The findings were similar to humans with severe obstructive lung disease. Microscopic examination substantiated the flow-volume measurements in that the main bronchi, small bronchi, and bronchioles were found to have an increase in dense fibrous tissue, while the alveolar level was characterized by destruction of alveolar walls and an increase in septal thickness. Thus a single exposure to MIC, if the concentration is high enough, is sufficient to induce permanent pulmonary toxicity.
Ferguson
J S
JS
Department of Industrial Environmental Health Sciences, Graduate School of Public Health, University of Pittsburgh, Pennsylvania 15261.
Alarie
Y
Y
D000280:Administration, Inhalation; D000818:Animals; D000986:Antisickling Agents / Q000008:administration & dosage / Q000633:toxicity*; D001835:Body Weight / Q000187:drug effects; D002245:Carbon Dioxide / Q000502:physiology; D003485:Cyanates / Q000008:administration & dosage / Q000633:toxicity*; D004801:Eosine Yellowish-(YS) / Q000378:metabolism; D006168:Guinea Pigs; D006416:Hematoxylin / Q000378:metabolism; D006651:Histocytochemistry; D017953:Isocyanates; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D007830:Larynx / Q000187:drug effects / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008168:Lung / Q000033:anatomy & histology / Q000187:drug effects* / Q000502:physiology; D008297:Male; D009929:Organ Size / Q000187:drug effects; D010101:Oxygen Consumption / Q000187:drug effects; D012119:Respiration / Q000187:drug effects / Q000502:physiology; D013154:Spleen / Q000187:drug effects / Q000378:metabolism; D013997:Time Factors
D000986:Antisickling Agents; D003485:Cyanates; D017953:Isocyanates; D002245:Carbon Dioxide; C008461:methyl isocyanate; D004801:Eosine Yellowish-(YS); D006416:Hematoxylin